We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ritract Limited today reported US Food & Drug Administration (FDA) clearance to begin marketing its range of auto-retractable safety syringes in the USA.
3M Co. on Thursday said it has entered into a definitive agreement to acquire the safety business of POMP Medical and Occupational Health Products LLC, including related trademarks and patents.
A nanoparticle-based drug delivery concept in which an applied magnetic field directs the accumulation in tumor cells of custom-designed, drug-filled nanocarriers has been demonstrated by University at Buffalo researchers.
SciClone Pharmaceuticals, Inc. today announced that it has entered into a three year agreement with Biocompatibles International plc. granting SciClone exclusive rights to market Biocompatibles' DC BeadTM chemotherapy releasing device within China, particularly for the minimally invasive treatment of malignant hypervascular tumors such as primary liver cancer, hepatocellular carcinoma (HCC).
As health care providers seek less cumbersome devices to treat kidney failure, Marshall-based Renal Solutions Inc. is promoting its mobile
kidney dialysis machines as a solution.
A law firm representing some of the plaintiffs in a lawsuit against Medtronic for sales of faulty heart devices has been removed from a plaintiff steering committee by the presiding judge.
Ortec International plans to file a humanitarian device exemption (HDE) application with the FDA for another version of its previously approved product to treat disfiguring skin burns, the company said May 30.
ReNu with MoistureLoc could still be purchased on the UK high street yesterday, more than three weeks after manufacturer Bausch & Lomb announced a worldwide product recall.
Advanced Medical Optics, Inc. (AMO), a global leader in ophthalmic surgical devices and eye care products, today reconfirmed its 2006 and 2007 revenue guidance and increased its 2006 and 2007 adjusted earnings-per-share guidance to reflect the impacts of the $450 million convertible senior subordinated note offering (plus up to an additional $50 million of notes subject to the initial purchasers option) purchase of $500 million worth of its common stock and intent to purchase up to $100 million of aggregate principal amount of its outstanding convertible notes.